Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor

Protein disulfide isomerase (PDI, PDIA1) is an emerging therapeutic target in oncology. PDI inhibitors have demonstrated a unique propensity to selectively induce apoptosis in cancer cells and overcome resistance to existing therapies, although drug candidates have not yet progressed to the stage of...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of medicinal chemistry Vol. 186; p. 111906
Main Authors:	Robinson, Reeder M., Reyes, Leticia, Duncan, Ravyn M., Bian, Haiyan, Strobel, Eric D., Hyman, Sarah L., Reitz, Allen B., Dolloff, Nathan G.
Format:	Journal Article
Language:	English
Published:	France Elsevier Masson SAS 15-01-2020
Subjects:	Bortezomib - chemical synthesis Bortezomib - chemistry Bortezomib - pharmacology Cell Line Cell Survival - drug effects Dose-Response Relationship, Drug Drug resistance ER stress Humans Isoenzymes - antagonists & inhibitors Isoenzymes - metabolism Molecular Structure Multiple myeloma Procollagen-Proline Dioxygenase - antagonists & inhibitors Procollagen-Proline Dioxygenase - metabolism Proteasome inhibitor Proteasome Inhibitors - chemical synthesis Proteasome Inhibitors - chemistry Proteasome Inhibitors - pharmacology Protein disulfide isomerase (PDI) Protein Disulfide-Isomerases - antagonists & inhibitors Protein Disulfide-Isomerases - metabolism Structure-Activity Relationship UPR ER stress Protein disulfide isomerase (PDI) Drug resistance Proteasome inhibitor UPR Multiple myeloma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!